Printer Friendly

ALPHA 1 BIOMEDICALS, INC. APPOINTS SUZANNE K. BECKNER AS DIRECTOR OF DEVELOPMENT

 BETHESDA, Md., June 30 /PRNewswire/ -- Alpha 1 Biomedicals, Inc. (NASDAQ: ALBM) announced today the appointment of Suzanne K. Beckner, Ph.D. as director of development. She will be responsible for managing new product development and supporting ongoing clinical trials programs.
 Dr. Beckner brings to the company a 20-year career in biotechnology research and product development. Most recently Dr. Beckner was director, Immunotherapy R&D with Cellco, Inc., where she managed the overall research and development activities of the company, expanding its cellular therapy technology. Previously she held positions with Life Technologies, Inc. as research director and then as business director of the Cellular Biochemistry Products business section. She also held research management positions with Biotherapeutics, Inc., the National Cancer Institute and the National Institutes of Health. Dr. Beckner received her Ph.D. in biochemistry from Georgetown University Medical School.
 Alpha 1 Biomedicals, Inc. is engaged in the development of pharmaceutical products for the treatment of chronic viral diseases, immune disorders and cancer. The company's lead drug, Thymosin alpha 1, is currently in U.S. clinical trials for the treatment of chronic hepatitis B, chronic hepatitis C and AIDS.
 -0- 6/30/93
 /CONTACT: Vincent F. Simmon, Ph.D., president and CEO of Alpha 1 Biomedicals, Inc., 301-564-4400; or Anita Monteith-Dixon of Long Ridge Associates, 203-790-0647, for Alpha 1 Biomedicals/
 (ALBM)


CO: Alpha 1 Biomedicals, Inc. ST: Maryland IN: MTC SU: PER

SM-LR -- NY007 -- 7017 06/30/93 09:14 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 30, 1993
Words:240
Previous Article:REUTERS APPOINTS NORTH AND LATIN AMERICAN MANAGERS
Next Article:HANSON TO ACQUIRE QUANTUM CHEMICAL IN MERGER VALUED AT APPROXIMATELY $3.2 BILLION
Topics:


Related Articles
ICN AND SUBSIDIARY COMPANIES ANNOUNCE MANAGEMENT APPOINTMENTS
ALPHA 1 BIOMEDICALS, INC. APPOINTS FRANK P. MAMARIL AS DIRECTOR OF QUALITY CONTROL
/FOLLOWING IS A REPEAT OF A RELEASE MOVED YESTERDAY/
ALPHA 1 BIOMEDICALS APPOINTS MARTIN ROSE SENIOR VICE PRESIDENT, CLINICAL AND REGULATORY AFFAIRS
ALPHA 1 BIOMEDICALS NAMES ERNEST R. TYLER VICE PRESIDENT, OPERATIONS
ALPHA-BETA TECHNOLOGY, INC. NAMES PAUL BLEICHER, M.D., PH.D. AS DIR. OF CLINICAL AFFAIRS, PARRISH GALLIHER AS DIR. OF MANUFACTURING DEVELOPMENT
ALPHA 1 BIOMEDICALS, INC. PROMOTES SUZANNE K. BECKNER TO VICE PRESIDENT, DEVELOPMENT
THYMOSIN ALPHA 1 COMBINATION STUDY SUGGESTS CD4+ RESPONSE
ALPHA 1 BI0MEDICALS, INC. APPOINTS MICHAEL L. BERMAN AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters